Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 575-584

  Frydecka, Dorota ^a   Misiak, Błażej ^a   Pawlak Adamska, Edyta ^b   Karabon, Lidia ^a,b   Tomkiewicz, Anna ^b   Sedlaczek, Paweł ^a   Kiejna, Andrzej ^a   Beszłej, Jan Aleksander ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Cognition; Digit symbol coding task; Gender differences; Gene polymorphism; TGF; Transforming growth factor beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MENTAL TASK; ONSET AGE; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TGFB1 GENE;

EID: 84929146264     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S74672     Document Type: Article

References (76)

1. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801–808.
2. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39(6):1174–1179.
3. Zakharyan R, Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry. 2014;15(3):174–187.
4. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–671.
5. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146.
6. Cai J, Schleidt S, Pelta-Heller J, Hutchings D, Cannarsa G, Iacovitti L. BMP and TGF-β pathway mediators are critical upstream regulators of Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells. Dev Biol. 2013;376(1):62–73.
7. Krieglstein K, Suter-Crazzolara C, Fischer WH, Unsicker K. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP + toxicity. EMBO J. 1995;14(4):736–742.
8. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS, Rosenthal A. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron. 1994;13(5):1245–1252.
9. Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res. 2010;122(1–3):38–42.
10. Umeda-Yano S, Hashimoto R, Yamamori H, et al. The regulation of gene expression involved in TGF-β signaling by ZNF804A, a risk gene for schizophrenia. Schizophr Res. 2013;146(1–3):273–278.
11. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A. 2007;104(24):10164–10169.
12. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66(8):1014–1020.
13. Yamada Y, Miyauchi A, Goto J, et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res. 1998;13(10):1569–1576.
14. Frydecka D, Misiak B, Beszlej JA, et al. Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia. Mol Biol Rep. 2013;40(10):5607–5614.
15. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–281.
16. Ongali B, Nicolakakis N, Lecrux C, et al. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer’s disease. The Am J Pathol. 2010;177(6):3071–3080.
17. Nicolakakis N, Aboulkassim T, Aliaga A, Tong XK, Rosa-Neto P, Hamel E. Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone. J Cereb Blood Flow Metab. 2011;31(1):200–211.
18. Arosio B, Bergamaschini L, Galimberti L, et al. +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution. Mech Ageing Dev. 2007;128(10):553–557.
19. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764–770.
20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
21. Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry. 1990;24:73–88.
22. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784–788.
23. Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Les problèmes [The psychological examination in cases of traumatic encephalopathy. Problems]. Archives de Psychologie. 1941;28:215–228. French.
24. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–394.
25. Benton AL. Differential behavioural effects in frontal lobe disease. Neuropsychologia. 1968;6:53–60.
26. Kessler J, Denzler P, Markowitsch HJ. Demenztest [Test for dementia]. Weinheim: Beltz Test GmbH; 1988. German.
27. Jensen AR. Scoring the Stroop test. Acta Psychol (Amst). 1965;24(5):398–408.
28. Brzeziński J, Hornowska E. Skala Inteligencji Wechslera dla Dorosłych. Wersja Zrewidowana. Polska Adaptacja WAIS-R (PL) [Scale of the Wechsler Adult Intelligence. The revised version. Polish adaptation WAIS-R (PL)]. Warszawa: Wydawnictwo Naukowe PWN; 1996. Polish.
29. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667.
30. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277–286.
31. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol. 2005;83(1):9–17.
32. Kim YK, Myint AM, Lee BH, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):1129–1134.
33. Borovcanin M, Jovanovic I, Radosavljevic G, et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012;46(11):1421–1426.
34. Borovcanin M, Jovanovic I, Radosavljevic G, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013;147(1):103–109.
35. Lin CC, Chang CM, Chang PY, Huang TL. Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gung Med J. 2011;34(4):375–381.
36. Hutchinson IV, Turner DM, Sankaran D, Awad MR, Sinnott PJ. Influence of cytokine genotypes on allograft rejection. Transplant Proc. 1998;30(3):862–863.
37. Han IB, Ropper AE, Jeon YJ, et al. Association of transforming growth factor-beta1 gene polymorphism with genetic susceptibility to ossification of the posterior longitudinal ligament in Korean patients. Genet Mol Res. 2013;12(4):4807–4816.
38. O’Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40(9):1053–1055.
39. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123–129.
40. Hare E, Glahn DC, Dassori A, et al. Heritability of age of onset of psychosis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2010;153 B(1):298–302.
41. Vassos E, Sham PC, Cai G, et al. Correlation and familial aggregation of dimensions of psychosis in affected sibling pairs from China. Br J Psychiatry. 2008;193(4):305–310.
42. Husted JA, Greenwood CM, Bassett AS. Heritability of schizophrenia and major affective disorder as a function of age, in the presence of strong cohort effects. Eur Arch Psychiatry Clin Neurosci. 2006;256(4):222–229.
43. Voisey J, Swagell CD, Hughes IP, Lawford BR, Young RM, Morris CP. A novel DRD2 single-nucleotide polymorphism associated with schizophrenia predicts age of onset: HapMap tag-single-nucleotide polymorphism analysis. Genet Test Mol Biomarkers. 2012;16(2):77–81.
44. Hanninen K, Katila H, Saarela M, et al. Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2008;258(1):10–15.
45. Sacchetti E, Bocchio-Chiavetto L, Valsecchi P, et al. G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun. 2007;21(4):450–457.
46. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;(213):11–37.
47. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16(1):27–34.
48. Ibrahim HM, Tamminga CA. Treating impaired cognition in schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1587–1594.
49. Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143(1):198–202.
50. Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci. Epub 2014 Sep 12.
51. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res. 2012;134(1):83–88.
52. Shirts BH, Prasad KM, Pogue-Geile MF, Dickerson F, Yolken RH, Nimgaonkar VL. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. Schizophr Res. 2008;106(2–3):268–274.
53. Okahisa Y, Ujike H, Kunugi H, et al. Leukemia inhibitory factor gene is associated with schizophrenia and working memory function. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):172–176.
54. Zhang XY, Tang W, Xiu MH, et al. Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls. Brain Behav Immun. 2013;32:105–111.
55. Asevedo E, Rizzo LB, Gadelha A, et al. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav. 2014;129:194–198.
56. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64(5):532–542.
57. Van Den Bossche MJ, Docx L, Morrens M, et al. Less cognitive and neurological deficits in schizophrenia patients carrying risk variant in ZNF804A. Neuropsychobiology. 2012;66(3):158–166.
58. Walters JT, Corvin A, Owen MJ, et al. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry. 2010;67(7):692–700.
59. Nicodemus KK, Elvevåg B, Foltz PW, Rosenstein M, Diaz-Asper C, Weinberger DR. Category fluency, latent semantic analysis and schizophrenia: a candidate gene approach. Cortex. 2014;55:182–191.
60. Balog Z, Kiss I, Kéri S. ZNF804A may be associated with executive control of attention. Genes Brain Behav. 2011;10(2):223–227.
61. Chen M, Xu Z, Zhai J, et al. Evidence of IQ-modulated association between ZNF804A gene polymorphism and cognitive function in schizophrenia patients. Neuropsychopharmacology. 2012;37(7):1572–1578.
62. Eriksson UK, Pedersen NL, Reynolds CA, et al. Associations of gene sequence variation and serum levels of C-reactive protein and interleukin-6 with Alzheimer’s disease and dementia. J Alzheimers Dis. 2011;23(2):361–369.
63. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses. 2014;7(4):223–230.
64. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22(5):417–428.
65. Markham JA. Sex steroids and schizophrenia. Rev Endocr Metab Disord. 2012;13(3):187–207.
66. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565–571.
67. Koster A, Lajer M, Lindhardt A, Rosenbaum B. Gender differences in first episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2008;43(12):940–946.
68. Thorup A, Petersen L, Jeppesen P, et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis. 2007;195(5):396–405.
69. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16(2):185–194.
70. Dluzen DE. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol. 2000;29(5–6):387–399.
71. Wu YC, Hill RA, Gogos A, van den Buuse M. Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience. 2013;239:67–83.
72. McNeil TF, Kaij L, Malmquist-Larsson A. Women with nonorganic psychosis: factors associated with pregnancy’s effect on mental health. Acta Psychiatr Scand. 1984;70(3):209–219.
73. Dhandapani KM, Wade FM, Mahesh VB, Brann DW. Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology. 2005;146(6):2749–2759.
74. Buchanan CD, Mahesh VB, Brann DW. Estrogen-astrocyte-luteinizing hormone-releasing hormone signaling: a role for transforming growth factor-beta(1). Biol Reprod. 2000;62(6):1710–1721.
75. Ying SY. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev. 1988;9(2):267–293.
76. Lv MH, Tan YL, Yan SX, et al. Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Psychopharmacology (Berl). Epub 2014 Jun 24.